A5084915025- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- T-cell and B-cell Immunology
- Radiopharmaceutical Chemistry and Applications
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Cytomegalovirus and herpesvirus research
- Mesenchymal stem cell research
- Virus-based gene therapy research
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Medical Imaging Techniques and Applications
- Transplantation: Methods and Outcomes
- Immunodeficiency and Autoimmune Disorders
Fred Hutch Cancer Center
2016-2025
University of Washington
2016-2025
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2013-2025
University of Washington Medical Center
2014-2023
Cancer Research Center
2008-2023
Cleveland Clinic
2023
Seattle University
2006-2019
Seattle Cancer Care Alliance
2012-2017
Hudson Institute
2016
John Wiley & Sons (United States)
2016
Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In present report we propose to define regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity (RIC), and (3) nonmyeloablative (NMA) conditioning. Assignment these categories is based on duration of cytopenia requirement (SC) support: MA cause irreversible SC support mandatory. NMA minimal cytopenia, can be given also without support. RIC...
Over the past decade, advances have been made in care of patients undergoing transplantation. We conducted a study to determine whether these improved outcomes transplantation.We analyzed overall mortality, mortality not preceded by relapse, recurrent malignant conditions, and frequency severity major complications transplantation, including graft-versus-host disease (GVHD) hepatic, renal, pulmonary, infectious complications, among 1418 who received their first allogeneic transplants at our...
During the 2006 BMT Tandem Meetings, a workshop was convened by Center for International Blood and Marrow Transplant Research (CIBMTR) to discuss conditioning regimen intensity define boundaries of reduced-intensity (RIC) before hematopoietic cell transplantation (HCT). The goal determine acceptance available RIC definitions in transplant community. Participants were surveyed regarding their opinions on specific statements intensity. Questions covered "Champlin criteria," as well operational...
Purpose Retrospective studies have shown similar survival among patients with acute myeloid leukemia (AML) and myelodysplasia (MDS) after nonmyeloablative compared myeloablative conditioning. Refined risk stratification is required to design prospective trials. Patients Methods We stratified outcomes AML (n = 391) or MDS 186) who received either 125) 452) allogeneic hematopoietic cell transplantation (HCT) based on comorbidities, as assessed by a HCT-specific comorbidity index (HCT-CI), well...
The majority of patients in need a hematopoietic-cell transplant do not have matched related donor. Data are needed to inform the choice among various alternative donor-cell sources.
Age has long been used as a major factor for assessing suitability allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making HCT is unknown.Data from 3,033 consecutive recipients HLA-matched grafts five institutions contributed this analysis. Patients were randomly divided into training set develop weights age intervals and...
We have used a nonmyeloablative conditioning regimen consisting of total-body irradiation (2 Gy) with or without fludarabine (30 mg/m(2)/d for 3 days) related and unrelated hematopoietic cell transplantation (HCT) in patients hematologic malignancies who were not candidates conventional HCT because age, medical comorbidities, preceding high-dose HCT. This approach relied on graft-versus-tumor (GVT) effects control malignancy.We analyzed GVT 322 given grafts from HLA-matched (n = 192) donors...
<h3>Context</h3>A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions.<h3>Objective</h3>To describe outcomes of 60 years after receiving HCT.<h3>Design, Setting, and Participants</h3>From 1998 2008, 372 aged 75 were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning low-dose total body...
Purpose We reported encouraging early results of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had advanced chronic lymphocytic leukemia (CLL). Here, we have extended the follow-up to a median 5 years and included data on an additional 18 patients. Patients Methods Eighty-two patients, age 42 72 years, fludarabine-refractory CLL were conditioned with 2 Gy total-body irradiation alone or combined fludarabine followed by HCT from...
Allogeneic hematopoietic cell transplantation is indicated for refractory hematologic cancer and some nonmalignant disorders. Survival limited by recurrent organ toxicity.To determine whether survival has improved over the past decade note impediments to better outcomes.The authors compared cohorts that had transplants during 2003 2007 versus 2013 2017. outcome measures were analyzed, along with transplant-related complications.A center performing allogeneic transplant procedures.All...
We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The allows the purest assessment graft-versus-tumor (GVT) effects apart from and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities.Patients received low-dose total-body irradiation ± fludarabine...